For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Tafamidis meglumine represents a true breakthrough . These innovative therapies stabilize the transthyretin protein, slowing its damaging build-up and reducing the severity of t